
	Application Number:	10/848,820
	Filing Date:	May 19, 2004
	First Named Inventor:	Timothy A. McKinsey
	Art Unit:	1614
	Examiner Name:	Unknown
Total Number of Pages in this Submission : _____		Attorney Docket Number: MYOG:044US

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> References B1-B5, C1-C25 <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Declaration(s) _____ <input type="checkbox"/> Copy of Notice of Missing Parts/Requirements	<input type="checkbox"/> Drawings(s) _____ <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <input type="checkbox"/> Check in the amount of \$ _____ <input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: 50-1212/MYOG:044US <input type="checkbox"/> Sequence Statement <input type="checkbox"/> Paper Copy of Sequence Listing <input type="checkbox"/> Computer Readable Form (CRF) <input checked="" type="checkbox"/> Postcard <input type="checkbox"/> _____ <input type="checkbox"/> _____
--	---	---


Remarks:

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski L.L.P.	Customer Number	32425
Signature			
Printed Name	Steven L. Highlander	Reg. No.	37,642
Date	May 2, 2006		

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or Printed Name	Steven L. Highlander	Date	May 2, 2006

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In re Application of:

Timothy A. McKinsey et al.

Serial No.: 10/848,820

Filed: May 19, 2004

For: INHIBITION OF PROTEIN KINASE C-MU (PKD) AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE



Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: MYOG:044US

**CERTIFICATE OF MAILING  
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

May 2, 2006

Date

Steven L. Highlander

**INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MYOG:044US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201


Date: May 2, 2006

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
MYOG:044USSerial No.  
10/848,820Applicant  
Timothy A. McKinsey *et al.*Filing Date:  
May 19, 2004Group:  
1614U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 2*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,196,265	04/01/80	Koprowski <i>et al.</i>	435	70.21	08/11/78
	A2	4,458,066	07/03/84	Caruthers <i>et al.</i>	536	25.34	03/24/81
	A3	4,415,723	11/15/83	Hedges <i>et al.</i>	528	204	03/19/82
	A4	4,873,191	10/10/89	Wagner <i>et al.</i>	800	25	08/18/86
	A5	5,354,855	10/11/94	Cech <i>et al.</i>	536	24.1	02/28/92
	A6	5,604,251	02/18/97	Heitsch <i>et al.</i>	514	396	06/07/95
	A7	5,795,715	08/18/98	Livache <i>et al.</i>	435	6	06/17/94
	A8	5,889,136	03/30/99	Scaringe <i>et al.</i>	536	25.34	06/09/95
	A9	5,955,501	09/21/99	Driedger <i>et al.</i>	514	533	06/07/95
	A10	6,043,270	03/28/00	Driedger <i>et al.</i>	514	450	06/07/95
	A11	6,080,784	06/27/00	Driedger <i>et al.</i>	514	546	06/07/95
	A12	6,441,020	08/27/02	Quick <i>et al.</i>	514	411	09/28/98
	A13	6,528,294	03/04/03	Li <i>et al.</i>	435	194	02/01/02

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 01/68836	09/20/01	WIPO			English
	B2	WO 01/36646	05/25/01	WIPO			English
	B3	WO 00/44914	08/03/00	WIPO			English
	B4	WO 99/32619	07/01/99	WIPO			English
	B5	WO 84/03564	09/13/84	WIPO			English

25435187.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. MYOG:044US	Serial No. 10/848,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Timothy A. McKinsey <i>et al.</i>	
		Filing Date: May 19, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Butler <i>et al.</i> , "Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo," <i>Cancer Res.</i> , 60:5165-5170, 2000.
	C2	Caplen <i>et al.</i> , "dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference," <i>Gene</i> , 252(1-2):95-105, 2000.
	C3	Coffey <i>et al.</i> , "The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid," <i>Cancer Res.</i> , 61:3591-3594, 2001.
	C4	Eichhorn and Bristow, "Medical therapy can improve the biological properties of the chronically failing heart," <i>Circulation</i> , 94:2285-2296, 1996.
	C5	Gao, <i>et al.</i> , "Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase," <i>J. Biol. Chem.</i> , 15:8675-81, 1996.
	C6	Grishok <i>et al.</i> , "Genetic requirements for inheritance of RNAi in <i>C. elegans</i> ," <i>Science</i> , 287:2494-2497, 2000.
	C7	Harlow and Lane, <i>Using Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, 1988.
	C8	Haworth <i>et al.</i> , "Expression and activity of protein kinase D/protein kinase C mu in myocardium: evidence for alpha1-adrenergic receptor- and protein kinase C-mediated regulation," <i>J. Mol. Cell. Cardiol.</i> , 32:1013-1023, 2000.
	C9	Hayashi <i>et al.</i> , "PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu," <i>Biochim. Biophys. Acta</i> , 1450:99-106, 1999.
	C10	Isselbacher <i>et al.</i> , <i>Harrison's Principles of Internal Medicine</i> , McGraw-Hill, NY, 416-431, 1994.
	C11	Johannes <i>et al.</i> , "PKCu is a novel, atypical member of the protein kinase C family," <i>J. Biol. Chem.</i> , 269(8):6140-8, 1994.
	C12	Katoh <i>et al.</i> , "MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression," <i>J. Biol. Chem.</i> , 273:15111-18, 1998.
	C13	Lu <i>et al.</i> , "Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases," <i>Proc. Natl. Acad. Sci. USA</i> , 97:4070-4075, 2000.

25435187.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. MYOG:044US	Serial No. 10/848,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant Timothy A. McKinsey <i>et al.</i>	
	Filing Date: May 19, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Marks <i>et al.</i> , "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells," <i>J. Natl. Cancer Inst.</i> , 92(15):1210-1216, 2000.
	C15	McKinsey <i>et al.</i> , "Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5," <i>Proc. Natl. Acad. Sci. USA</i> , 97:14400-14405, 2000.
	C16	McKinsey <i>et al.</i> , "Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation," <i>Nature</i> , 408:106-111, 2000b.
	C17	Montgomery <i>et al.</i> , "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 95:15502-15507, 1998.
	C18	Nishikawa <i>et al.</i> , "Determination of the specific substrate sequence motifs of protein kinase C isozymes," <i>J. Biol. Chem.</i> , 276:3310-3318, 1997.
	C19	Sturany <i>et al.</i> , "Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases," <i>J. Biol. Chem.</i> , 276:3310-3318, 2001.
	C20	Taunton <i>et al.</i> , "A mammalian histone deacetylase related to the yeast transcriptional regulator rpd3p," <i>Science</i> , 272:408-411, 1996.
	C21	Tong <i>et al.</i> , "Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain," <i>Nucleic Acids Res.</i> , 30:1114-23, 2002.
	C22	Valverde <i>et al.</i> , "Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain," <i>Proc. Natl. Acad. Sci. USA</i> , 91(18):8572-6, 1994.
	C23	Van Lint <i>et al.</i> , "Protein kinase D: an intracellular traffic regulator on the move," <i>Trends in Cell. Biol.</i> , 12:193-200, 2002.
	C24	Van den Wyngaert <i>et al.</i> , "Cloning and characterization of human histone deacetylase 8," <i>FEBS Lett.</i> , 478:77-83, 2000.
	C25	Zhang <i>et al.</i> , "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy," <i>Cell</i> , 110:479-488, 2002.

25435187.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.